Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

122.56
+4.413.73%
Pre-market: 122.05-0.5100-0.42%06:30 EST
Volume:6.28M
Turnover:763.77M
Market Cap:152.06B
PE:19.08
High:122.75
Open:118.61
Low:118.58
Close:118.15
52wk High:124.61
52wk Low:86.08
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.84
T/O Rate:0.51%
Dividend:3.14
Dividend Rate:2.56%
EPS(TTM):6.42
EPS(LYR):0.3849
ROE:40.71%
ROA:12.57%
PB:7.06
PE(LYR):318.40

Loading ...

Gilead Sciences Inc. Stock Advances 3.7%, Outperforms Market

Dow Jones
·
15 hours ago

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST on 2025-11-11

Reuters
·
17 hours ago

Assembly Biosciences Q3 net loss narrows, raises $175 mln

Reuters
·
Yesterday

Gilead CFO Says Co Will Continue to Be Active in Business Development, Both in Licensing and Acquisitions

THOMSON REUTERS
·
Yesterday

Gilead CFO Says Co Has More Than 10 Programs in Development in Hiv

THOMSON REUTERS
·
Yesterday

Gilead CFO Says Hiv Business Is NOW Projected to Grow 5% This Year - Conf Call

THOMSON REUTERS
·
Yesterday

Gilead CFO Says Medicare Reform Is About $900 Mln Headwind for Hiv Business, $1.2 Bln Headwind for Business Overall

THOMSON REUTERS
·
Yesterday

Clinical-stage cancer immunotherapy firm Compugen's Q3 net loss widens

Reuters
·
Nov 10

Nurix Therapeutics Appoints Roger Dansey to Board of Directors

Reuters
·
Nov 10

Compugen reports third quarter revenue of $1.9 million and cash position of $86.1 million

Reuters
·
Nov 10

Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $153 From $143

MT Newswires Live
·
Nov 10

BRIEF-Gilead In Oct, Reached Settlement With A Tax Authority Related To A Prior Year Legal Entity Restructuring - Filing

Reuters
·
Nov 08

Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Nov 08

Gilead: in Oct, Reached Settlement With a Tax Authority Related to a Prior Year Legal Entity Restructuring - Filing

THOMSON REUTERS
·
Nov 08

Gilead: Sees $450 Mln of Income Tax Benefit and a Corresponding $530 Mln Reduction in Unrecognized Tax Benefits in Qtr Ending Dec 31- Filing

THOMSON REUTERS
·
Nov 08

Sector Update: Health Care Stocks Retreat Friday Afternoon

MT Newswires Live
·
Nov 08

Gilead Sciences Shares Fall 2.2% After Breast Cancer Drug Fails to Meet Main Goal of Late-Stage Study

THOMSON REUTERS
·
Nov 07

Gilead Sciences Says Trodelvy Misses Goal in Post-Endocrine Therapy Breast Cancer Study

MT Newswires Live
·
Nov 07

BRIEF-Gilead Provides Update on Phase 3 ASCENT-07 Study

Reuters
·
Nov 07

Gilead's breast cancer drug fails to meet main goal of late-stage study

Reuters
·
Nov 07